共 50 条
- [41] Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis)FRONTIERS IN MEDICINE, 2023, 10Gargiulo, LuigiNarcisi, AlessandraIbba, LucianoBalato, AnnaBianchi, LucaBrianti, PinaBuononato, DarioBurlando, MartinaCaldarola, GiacomoCampanati, AnnaCampione, ElenaCarrera, Carlo G.Carugno, AndreaCristaudo, AntonioCusano, FrancescoDapavo, PaoloDattola, AnnunziataDe Simone, ClaraGaiani, Francesca M.Gisondi, PaoloGiunta, AlessandroLoconsole, FrancescoMaione, VincenzoMortato, EdoardoMarzano, Angelo V.Maurelli, MartinaMegna, MatteoMercuri, Santo R.Offidani, AnnamariaOrsini, DiegoParodi, AuroraPellacani, GiovanniPotestio, LucaQuaglino, PietroRichetta, Antonio G.Romano, FrancescaSena, PaoloVenturini, MarinaMalagoli, PiergiorgioCostanzo, Antonio
- [42] COST-EFFECTIVENESS ANALYSIS OF BIMEKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN GREECEVALUE IN HEALTH, 2022, 25 (12) : S74 - S74Koulentaki, M.Tzanetakos, C.Stratigos, A.Sotiriou, E.Ladha, IChristou, P.Relakis, J.Kourlaba, G.
- [43] Bimekizumab efficacy in subgroups defined by prior systemic treatment in patients with moderate to severe plaque psoriasisJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB146 - AB146Rosmarin, DavidLebwohl, MarkFeldman, Steven R.Staubach-Renz, PetraDavis, LeahWixted, KristaMadden, CynthiaGomez, Natalie NunezPinter, Andreas
- [44] Psoriasis Symptoms and Impacts Measure (P-SIM) responses from the BE SURE bimekizumab in moderate to severe plaque psoriasis phase 3 trialJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB138 - AB138Warren, Richard B.Augustin, MatthiasGottlieb, Alice B.Duffin, Kristina CallisCiaravino, ValerieCioffi, ChristopherPeterson, LukeBlauvelt, Andrew
- [45] Efficacy and safety of bimekizumab for the treatment of psoriasis: a systematic review and meta-analysis of randomized clinical trialsJOURNAL OF DERMATOLOGICAL TREATMENT, 2023, 34 (01)Qiu, YuanyuanZhu, YangLiu, YunLiu, Qiliang
- [46] Bimekizumab in moderate-to-severe plaque psoriasis: evaluation of clinical and molecular evidence to understand maintenance of responseBRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (01) : E39 - E39Kreuger, J.Oliver, R.Glatt, S.Page, M.Edwards, H.Garcet, S.Dizier, B.Maroof, A.Shaw, S.
- [47] Psoriasis Symptoms and Impacts Measure (P-SIM) responses from the BE VIVID bimekizumab in moderate to severe plaque psoriasis phase 3 trialJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB137 - AB137Warren, Richard B.Langley, Richard G.Asahina, AkihikoAugustin, MatthiasMerola, Joseph F.Gottlieb, Alice B.Ciaravino, ValerieCioffi, ChristopherPeterson, LukeLebwohl, Mark
- [48] Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: a meta-analysis of randomized clinical trialsTHERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2023, 14Wang, YuqianLi, ShengBai, JuanCai, XiaoxuanTang, ShunliLin, PeiyiSun, QingmiaoQiao, JianjunFang, Hong
- [49] BIMEKIZUMAB EFFICACY IN MODERATE TO SEVERE PLAQUE PSORIASIS: IMPROVEMENTS IN FATIGUE OBSERVED IN TWO PHASE 3 STUDIESACTA DERMATO-VENEREOLOGICA, 2024, 104Gottlieb, Alice B.Augustin, MatthiasLambert, JoPinter, AndreasSavage, Laura J.Tsai, Tsen-FangFoley, PeterPaul, CarleWarham, RhysLambert, JeremyWiegratz, SusanneStahle, Mona
- [50] Bimekizumab in moderate-to-severe plaque psoriasis: evaluation of clinical and molecular evidence to understand maintenance of responseBRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (01) : E48 - E48Kreuger, J.Oliver, R.Glatt, S.Page, M.Edwards, H.Garcet, S.Dizier, B.Maroof, A.Shaw, S.